Proteomic biomarkers of adverse pregnancy outcome in preterm birth: A theranostics opportunity

Expert Review of Obstetrics and Gynecology

Volumn 2, Issue 6, 2007, Pages 743-753

  Buhimschi, Catalin S ^a   Buhimschi, Irina A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amniocentesis; amniotic fluid; inflammation; innate immunity; proteomics; theranostics

Indexed keywords

EID: 77951698656     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/17474108.2.6.743     Document Type: Article

References (89)

1. Martin JA, Hamilton BE, Sutton PD. Births: final data for 2004. National Vital Statistics Reports 55, 1–101 (2006).
2. Flores-Santos R, Hernandez-Cabrera MA, Hernandez-Herrera RJ. Screening for retinopathy of prematurity: results of a 7-year study of underweight newborns. Arch. Med. Res. 38, 440–443 (2007).
3. Patra K, Wilson-Costello D, Taylor HG. Grades I–II intraventricular hemorrhage in extremely low birth weight infants: effects on neurodevelopment. J. Pediatr. 149, 169–173 (2006).
4. Hintz SR, Kendrick DE, Vohr BR; National Institute of Child Health and Human Development Neonatal Research Network. Changes in neurodevelopmental outcomes at 18–22 months’ corrected age among infants of less than 25 weeks’ gestational age born in 1993–1999. Pediatrics 115, 1645–1651 (2005).
5. Vincer MJ, Allen AC, Joseph KS. Increasing prevalence of cerebral palsy among very preterm infants: a population-based study. Pediatrics 118, E1621 –E1626 (2006).
6. Bhandari A, Bhandari V. Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front. Biosci. 8, E370 –E380 (2003).
7. Clements KM, Barfield WD, Ayadi MF. Preterm birth-associated cost of early intervention services: an analysis by gestational age. Pediatrics 119, e866 –e874 (2007).
8. Green NS, Damus K, Simpson JL; March of Dimes Scientific Advisory Committee on Prematurity. Research agenda for preterm birth: recommendations from the March of Dimes. Am. J. Obstet. Gynecol. 193, 626–635 (2005).
9. Berghella V, Owen J, MacPherson C. Natural history of cervical funneling in women at high risk for spontaneous preterm birth. Obstet. Gynecol. 109, 863–869 (2007).
10. Klebanoff M, Searle K. The role of inflammation in preterm birth – focus on periodontitis. Br. J. Obstet. Gynecol. 113, 43–45 (2006).
11. Menon R, Fortunato SJ, Thorsen P. Genetic associations in preterm birth: a primer of marker selection, study design, and data analysis. J. Soc. Gynecol. Investig. 13, 531–541 (2006).
12. Husslein P, Cabero Roura L, Dudenhausen JW. Atosiban versus usual care for the management of preterm labor. J. Perinat. Med. 35, 305–313 (2007).
13. Smith GN, Walker MC, Ohlsson A. Randomized double-blind placebo-controlled trial of transdermal nitroglycerin for preterm labor. Am. J. Obstet. Gynecol. 196 (37) E1 –E8 (2007).
14. Berghella V, Rust OA, Althuisius SM. Short cervix on ultrasound: does indomethacin prevent p,eterm birth? Am. J. Obstet. Gynecol. 195, 809–813 (2006).
15. Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet. Gynecol. 108, 986–989 (2006).
16. Thornton JG. Maintenance tocolysis. Br. J. Obstet. Gynecol. 112, 118–121 (2005).
17. Hollier LM. Preventing preterm birth: what works, what doesn’t. Obstet. Gynecol. Surv. 60, 124–131 (2005).
18. Coomarasamy A, Knox EM, Gee H. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta-analysis with an indirect comparison of randomised trials. Br. J. Obstet. Gynecol. 110, 1045–1049 (2003).
19. King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst. Rev. 2, CD001992 (2005).
20. Combs CA, McCune M, Clark R, Fishman A. Aggressive tocolysis does not prolong pregnancy or reduce neonatal morbidity after preterm premature rupture of the membranes. Am. J. Obstet. Gynecol. 190, 1723–1728 (2004).
21. Lockwood CJ. Testing for risk of preterm delivery. Clin. Lab. Med. 23, 345–360 (2003).
22. Lockwood CJ, Kuczynski E. Markers of risk for preterm delivery. J. Perinat. Med. 27, 5–20 (1999).
23. Lockwood CJ, Kuczynski E. Risk stratification and pathological mechanisms in preterm delivery. Paediatr. Perinat. Epidemiol. 15, 78–89 (2001).
24. US Department of Health and Human Services. ‘Innovation or Stagnation? – Challenge and Opportunity on the Critical Path to New Medical Products. March 2004.
25. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
26. Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
27. Nesin M. Genetic basis of preterm birth. Front. Biosci. 12, 115–124 (2007).
28. Lee SJ, Steer PJ, Filippi V. Seasonal patterns and preterm birth: a systematic review of the literature and an analysis in a London-based cohort. Br. J. Obstet. Gynecol. 113, 1280–1288 (2006).
29. Gilbreath S, Kass PH. Adverse birth outcomes associated with open dumpsites in Alaska Native Villages. Am. J. Epidemiol. 164, 518–528 (2006).
30. Macones GA, Parry S, Elkousy M. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene–environment interaction in the etiology of spontaneous preterm birth. Am. J. Obstet. Gynecol. 190, 1504–1508 (2004).
31. Venter JC, Adams MD, Myers EW. The sequence of the human genome. Science 291, 1304–1351 (2001).
32. Aguan K, Carvajal JA, Thompson LP. Application of a functional genomics approach to identify differentially expressed genes in human myometrium during pregnancy and labour. Mol. Hum. Reprod. 6, 1141–1145 (2000).
33. Bukowski R, Hankins GD, Saade GR. Labor-associated gene expression in the human uterine fundus, lower segment, and cervix. PLoS Med. 3, E169 (2006).
34. Havelock JC, Keller P, Muleba N. Human myometrial gene expression before and during parturition. Biol. Reprod. 72, 707–719 (2005).
35. Buhimschi CS, Mason CW, Swaan PW. Evidence that innate immunity is activated in myometrium from women in term and preterm labor. Presented at: Society for Gynecologic Investigation. Toronto, Canada, 22–25 March 2006.
36. Lieber CD. Introduction to Proteomics. Tools for the New Biology. Lieber CD (Ed.). Humana Press Inc., NJ, USA, 3–14 (2002).
37. Buhimschi CS, Weiner CP, Buhimschi IA. Clinical proteomics: a novel diagnostic tool for the new biology of preterm labor, part I: proteomics tools. Obstet. Gynecol. Surv. 61, 481–486 (2006).
38. Bahtiyar MO, Copel JA, Mahoney MJ. Proteomics: a novel methodology to complement prenatal diagnosis of chromosomal abnormalities and inherited human diseases. Am. J. Perinatol. 24, 167–181 (2007).
39. Shankar R, Cullinane F, Brennecke SP, Moses EK. Applications of proteomic methodologies to human pregnancy research: a growing gestation approaching delivery? Proteomics 4, 1909–1917 (2004).
40. Menon R, Fortunato SJ. Infection and the role of inflammation in preterm premature rupture of the membranes. Best Pract. Res. Clin. Obstet. Gynaecol. 21, 467–478 (2007).
41. Bernstein S, Heimler R, Sasidharan P. Approaching the management of the neonatal intensive care unit graduate through history and physical assessment. Ped. Clin. North Am. 45, 79–105 (1998).
42. Mercer BM. Is there a role for tocolytic therapy during conservative management of preterm premature rupture of the membranes? Clin. Obstet. Gynecol. 50, 487–496 (2007).
43. Buhimschi IA, Kramer WB, Buhimschi CS. Reduction–oxidation (redox) state regulation of matrix metalloproteinase activity in human fetal membranes. Am. J. Obstet. Gynecol. 182, 458–464 (2000).
44. Wilkins MR, Sanchez JC, Gooley AA. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev. 13, 19–50 (1996).
45. Buhimschi IA, Christner R, Buhimschi CS. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. Br. J. Obstet. Gynecol. 112, 173–181 (2005).
46. Vuadens F, Benay C, Crettaz D. Identification of biologic markers of the premature rupture of fetal membranes: proteomic approach. Proteomics 3, 1521–1525 (2003).
47. TM isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis 27, 1169–11681 (2006).
48. Buhimschi IA, Buhimschi CS, Weiner CP. Proteomic but not enzyme-linked immunosorbent assay technology detects amniotic fluid monomeric calgranulins from their complexed calprotectin form. Clin. Diagn. Lab. Immunol. 12, 837–844 (2005).
49. Gravett MG, Novy MJ, Rosenfeld RG. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 292, 462–469 (2005).
50. Ruetschi U, Rosen A, Karlsson G. Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J. Proteome Res. 4, 2236–2242 (2005).
51. Biron DG, Brun C, Lefevre T. The pitfalls of proteomics experiments without the correct use of bioinformatics tools. Proteomics 6, 5577–5596 (2006).
52. Hermjakob H, Apweiler R. The Proteomics Identifications Database (PRIDE) and the ProteomExchange Consortium: making proteomics data accessible. Expert Rev. Proteomics 3, 1–3 (2006).
53. Lo SL, You T, Lin Q. SPLASH: Systematic Proteomics Laboratory Analysis and Storage Hub. Proteomics 6, 1758–1769 (2006).
54. Morita A, Miyagi E, Yasumitsu H. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 6, 5880–5890 (2006).
55. Zhang H, Kong B, Qu X, Jia L. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol. Oncol. 102, 61–66 (2006).
56. Taguchi F, Solomon B, Gregorc V. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J. Natl Cancer Inst. 99, 838–846 (2007).
57. Hellstrom M, Lexander H, Franzen B. Proteomics in prostate cancer research. Anal. Quant. Cytol. Histol. 29, 32–40 (2007).
58. Lopez MF, Mikulskis A, Kuzdzal S. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin. Chem. 51, 1946–1954 (2005).
59. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl Cancer Inst. 97, 315–319 (2005).
60. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845–867 (2002).
61. Sampson JE, Theve RP, Blatman RN. Fetal origin of amniotic fluid polymorphonuclear leukocytes. Am. J. Obstet. Gynecol. 176, 77–81 (1997).
62. Buhimschi CS, Pettker CM, Magloire LK. Proteomic technology and delayed interval delivery in multiple pregnancies. Int. J. Gynaecol. Obstet. 90, 48–50 (2005).
63. Cho CKJ, Shan SJ, Winsor EJ, Diamandis EP. Proteomic analysis of human amniotic fluid. Mol. Cell. Proteomics 6, 1406–1415 (2007).
64. Michaels JE, Dasari S, Pereira L. Comprehensive proteomic analysis of the human amniotic fluid proteome: gestational age-dependent changes. J. Proteome Res. 6, 1277–1285 (2007).
65. Buhimschi CS, Bhandari V, Hamar BD. Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. PLoS Med. 4 (1), e18 (2007).
66. Buhimschi CS, Buhimschi IA, Abdel-Razeq S. Proteomic biomarkers of intra-amniotic inflammation: relationship with funisitis and early-onset sepsis in the premature neonate. Pediatr. Res. 61, 318–324 (2007).
67. Hofmann MA, Drury S, Fu C. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889–901 (1999).
68. Buhimschi IA, Zhao G, Pettker CM. The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and inflammation. Am. J. Obstet. Gynecol. 196 (181), E1 –E13 (2007).
69. Lockwood CJ. Pregnancy-associated changes in the hemostatic system. Clin. Obstet. Gynecol. 49, 836–843 (2006).
70. Salafia CM, Lopez-Zeno JA, Sherer DM. Histologic evidence of old intrauterine bleeding is more frequent in prematurity. Am. J. Obstet. Gynecol. 173, 1065–1070 (1995).
71. Lockwood CJ, Krikun G, Rahman M. The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. Semin. Thromb. Hemost. 33, 111–117 (2007).
72. Weiner CP, Lee KY, Buhimschi CS. Proteomic biomarkers that predict the clinical success of rescue cerclage. Am. J. Obstet. Gynecol. 192, 710–718 (2005).
73. Lockwood CJ, Toti P, Arcuri F. Mechanisms of abruption-induced premature rupture of the fetal membranes: thrombin-enhanced interleukin-8 expression in term decidua. Am. J. Pathol. 167, 1443–1449 (2005).
74. Buhimschi IA, Christner R, Buhimschi CS. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. Br. J. Obstet. Gynecol. 112, 173–181 (2005).
75. Buhimschi CS, Sfakianaki AK, Hamar BG. A low vaginal ‘pool’ amniotic fluid glucose measurement is a predictive but not a sensitive marker for infection in women with preterm premature rupture of membranes. Am. J. Obstet. Gynecol. 194, 309–316 (2006).
76. Lewis DF, Robichaux AG, Jaekle RK. Expectant management of preterm premature rupture of membranes and nonvertex presentation: what are the risks? Am. J. Obstet. Gynecol. 196 (566), E1 –E5 (2007).
77. Mercer BM. Is there a role for tocolytic therapy during conservative management of preterm premature rupture of the membranes? Clin. Obstet. Gynecol. 50, 487–496 (2007).
78. ACOG Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician–gynecologists. Obstet. Gynecol. 109, 1007–1019 (2007).
79. Menon R, Fortunato SJ. The role of matrix degrading enzymes and apoptosis in rupture of membranes. J. Soc. Gynecol. Investig. 11, 427–437 (2004).
80. Thadikkaran L, Crettaz D, Siegenthaler MA. The role of proteomics in the assessment of premature rupture of fetal membranes. Clin. Chim. Acta 360, 27–36 (2005).
81. Buhimschi IA, Buhimschi CS, Norwitz E. Proteomic analysis of cervico–vaginal secretions during pregnancy. Presented at: The Society for Maternal–Fetal Medicine, Reno, NV, USA, 7–12 February 2005.
82. Di Quinzio MK, Oliva K, Holdsworth SJ. Proteomic analysis and characterisation of human cervico–vaginal fluid proteins. Clin. Aust. NZ J. Obstet. Gynaecol. 47, 9–15 (2007).
83. Pereira L, Reddy AP, Jacob T. Identification of novel protein biomarkers of preterm birth in human cervical–vaginal fluid. J. Proteome Res. 6, 1269–1276 (2007).
84. Buhimschi IA, Buhimschi CS, Weiner CP. Proteomic but not enzyme-linked immunosorbent assay technology detects amniotic fluid monomeric calgranulins from their complexed calprotectin form. Clin. Diagn. Lab. Immunol. 12, 837–844 (2005).
85. Kunimi K, Maegawa M, Kamada M. Myeloid-related protein-8/14 is associated with proinflammatory cytokines in cervical mucus. J. Reprod. Immunol. 71, 3–11 (2006).
86. ExPASy Proteomics Server. www.expasy.ch
87. European Bioinformatics Institute. www.ebi.ac.uk
88. Melanie 2D gel analysis. http://ca.expasy.org/melanie
89. ACS Publications. http://pubs.acs.org